Literature DB >> 100122

The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs.

R F Meenan, E H Yelin, C J Henke, D L Curtis, W V Epstein.   

Abstract

To detail the cost for one year of a chronic disease, 50 patients with Stage III rheumatoid arthritis were surveyed. Direct medical costs for this group were three times the national average, and 58% of these costs were covered by insurance. Indirect costs due to lost income were at least three times the direct medical costs, and transfer payments covered only 42% of these costs. Fifty-eight percent of the study group also sustained a major psychosocial loss. Uncovered income losses were the greatest economic burden for individuals with chronic rheumatoid arthritis. This striking ratio of indirect to direct medical costs has important implications for medical practice and health policy.

Entities:  

Mesh:

Year:  1978        PMID: 100122     DOI: 10.1002/art.1780210714

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  20 in total

1.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

2.  [Conceptual and methodological basics of cost assessments in rheumatology].

Authors:  J Ruof; J L Hülsemann; T Mittendorf; J-M von der Schulenburg; H Zeidler; S Merkesdal
Journal:  Z Rheumatol       Date:  2004-10       Impact factor: 1.372

Review 3.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

Authors:  Marco Barbieri; John B Wong; Michael Drummond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Sensory and vascular changes in a rat monoarthritis model: prophylactic and therapeutic effects of meloxicam.

Authors:  Javeria Ali Hashmi; Kiran Yashpal; David W Holdsworth; James L Henry
Journal:  Inflamm Res       Date:  2010-03-28       Impact factor: 4.575

Review 6.  Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).

Authors:  H A Wynne; M Campbell
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

Review 7.  The costs of rheumatoid arthritis.

Authors:  S H Allaire; M J Prashker; R F Meenan
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

8.  Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity.

Authors:  S M M Verstappen; A Boonen; H Verkleij; J W J Bijlsma; E Buskens; J W G Jacobs
Journal:  Ann Rheum Dis       Date:  2005-04-28       Impact factor: 19.103

9.  Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.

Authors:  D Huscher; S Merkesdal; K Thiele; H Zeidler; M Schneider; A Zink
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

10.  Prevalence of rheumatoid arthritis in the adult Indian population.

Authors:  A N Malaviya; S K Kapoor; R R Singh; A Kumar; I Pande
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.